-
1
-
-
16644385307
-
The relationship between hyperinsulinemia, hypertension and progressive renal disease
-
El-Atat FA, Stas SN, McFarlane SI et al. The relationship between hyperinsulinemia, hypertension and progressive renal disease. J Am Soc Nephrol 2004; 15: 2816-2827
-
(2004)
J Am Soc Nephrol
, vol.15
, pp. 2816-2827
-
-
El-Atat, F.A.1
Stas, S.N.2
McFarlane, S.I.3
-
2
-
-
0032512094
-
Pathophysiology of progressive nephropathies
-
Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. New Engl J Med 1998; 339: 1448-1456
-
(1998)
New Engl J Med
, vol.339
, pp. 1448-1456
-
-
Remuzzi, G.1
Bertani, T.2
-
3
-
-
79953053474
-
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: A post hoc analysis of the combined RENAAL and IDNT trials
-
Holtkamp FA, de Zeeuw D, de Graeff PA et al. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. Eur Heart J 2011; 32: 1493-1499
-
(2011)
Eur Heart J
, vol.32
, pp. 1493-1499
-
-
Holtkamp, F.A.1
De Zeeuw, D.2
De Graeff, P.A.3
-
4
-
-
34248178511
-
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: Post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
-
Eijkelkamp WB, Zhang Z, Remuzzi G et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007; 18: 1540-1546
-
(2007)
J Am Soc Nephrol
, vol.18
, pp. 1540-1546
-
-
Eijkelkamp, W.B.1
Zhang, Z.2
Remuzzi, G.3
-
5
-
-
9644294206
-
Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: A post hoc analysis of the RENAAL trial results
-
RENAAL Study Group
-
Remuzzi G, Ruggenenti P, Perna A et al; RENAAL Study Group. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. J Am Soc Nephrol 2004; 15: 3117-3125
-
(2004)
J Am Soc Nephrol
, vol.15
, pp. 3117-3125
-
-
Remuzzi, G.1
Ruggenenti, P.2
Perna, A.3
-
6
-
-
4344621497
-
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy
-
de Zeeuw D, Remuzzi G, Parving HH et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921-927
-
(2004)
Circulation
, vol.110
, pp. 921-927
-
-
De Zeeuw, D.1
Remuzzi, G.2
Parving, H.H.3
-
7
-
-
2442680120
-
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL
-
de Zeeuw D, Remuzzi G, Parving HH et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309-2320
-
(2004)
Kidney Int
, vol.65
, pp. 2309-2320
-
-
De Zeeuw, D.1
Remuzzi, G.2
Parving, H.H.3
-
8
-
-
0035922444
-
Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbersartan on the development of diabetic nephropathy in patients with type 2 diabetes
-
Parving HH, Lehnert H, Bröchner-Mortensen J et al. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbersartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878
-
(2001)
N Engl J Med
, vol.345
, pp. 870-878
-
-
Parving, H.H.1
Lehnert, H.2
Bröchner-Mortensen, J.3
-
9
-
-
0034113852
-
Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: A systematic overview of randomized placebo controlled trials
-
Kshirsagar AV, Joy MS, Hogan SL et al. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: a systematic overview of randomized placebo controlled trials. Am J Kidney Dis 2000; 35: 695-707
-
(2000)
Am J Kidney Dis
, vol.35
, pp. 695-707
-
-
Kshirsagar, A.V.1
Joy, M.S.2
Hogan, S.L.3
-
10
-
-
0038188560
-
Retarding progression of chronic renal disease: The neglected issue of residual proteinuria
-
Ruggenenti P, Perna A, Remuzzi G. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 2003; 63: 2254-2261
-
(2003)
Kidney Int
, vol.63
, pp. 2254-2261
-
-
Ruggenenti, P.1
Perna, A.2
Remuzzi, G.3
-
11
-
-
34249702586
-
Surrogate end points for clinical trials of kidney disease progression
-
Stevens LA, Greene T, Levey AS. Surrogate end points for clinical trials of kidney disease progression. Clin J Am Soc Nephrol 2006; 1: 874-884
-
(2006)
Clin J Am Soc Nephrol
, vol.1
, pp. 874-884
-
-
Stevens, L.A.1
Greene, T.2
Levey, A.S.3
-
12
-
-
0036435819
-
Renal damage associated with proteinuria
-
Praga M, Morales E. Renal damage associated with proteinuria. Kidney Int 2002; 62: S42-S46
-
(2002)
Kidney Int
, vol.62
, pp. S42-S46
-
-
Praga, M.1
Morales, E.2
-
13
-
-
0035902622
-
Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data
-
Jafar TH, Schmid CH, Landa M et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73-87
-
(2001)
Ann Intern Med
, vol.135
, pp. 73-87
-
-
Jafar, T.H.1
Schmid, C.H.2
Landa, M.3
-
14
-
-
13244298395
-
Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease
-
Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertension 2005; 18: 44-49
-
(2005)
Am J Hypertension
, vol.18
, pp. 44-49
-
-
Sato, A.1
Hayashi, K.2
Saruta, T.3
-
15
-
-
2342559832
-
The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: A randomized controlled study
-
Rachmani R, Slavachevsky I, Amit M et al. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study. Diabet Med 2004; 21: 471-475
-
(2004)
Diabet Med
, vol.21
, pp. 471-475
-
-
Rachmani, R.1
Slavachevsky, I.2
Amit, M.3
-
16
-
-
24144495285
-
Beneficial effects of adding spironolactone to recomendad antihypertensive treatment in diabetic nephopathy: A randomized, double-masked, cross over study
-
Rossing K, Schjoedt KJ, Smidt UM et al. Beneficial effects of adding spironolactone to recomendad antihypertensive treatment in diabetic nephopathy: a randomized, double-masked, cross over study. Diabetes Care 2005; 28: 2106-2112
-
(2005)
Diabetes Care
, vol.28
, pp. 2106-2112
-
-
Rossing, K.1
Schjoedt, K.J.2
Smidt, U.M.3
-
17
-
-
33746558934
-
Double-blind, placebo controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy with or without an angiotensin II receptor blocker
-
Crysostomou A, Pedagogos E, MacGregor L et al. Double-blind, placebo controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006; 1: 256-262
-
(2006)
Clin J Am Soc Nephrol
, vol.1
, pp. 256-262
-
-
Crysostomou, A.1
Pedagogos, E.2
MacGregor, L.3
-
19
-
-
72049109463
-
Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensinconverting enzyme inhibition in diabetic nephropathy
-
Mehdi UF, Adams-Huet B, Raskin P et al. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensinconverting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 2009; 20: 2641-2650
-
(2009)
J Am Soc Nephrol
, vol.20
, pp. 2641-2650
-
-
Mehdi, U.F.1
Adams-Huet, B.2
Raskin, P.3
-
20
-
-
38149030811
-
Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: A systematic review
-
Bomback AS, Kshirsagar AV, Amamoo MA et al. Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 2008; 51: 199-211
-
(2008)
Am J Kidney Dis
, vol.51
, pp. 199-211
-
-
Bomback, A.S.1
Kshirsagar, A.V.2
Amamoo, M.A.3
-
21
-
-
84923834917
-
Aldosterone antagonists for preventing the progression of chronic kidney disease
-
Bolignano D, Palmer SC, Navaneethan SD et al. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev 2014; 4: CD007004
-
(2014)
Cochrane Database Syst Rev
, vol.4
, pp. CD007004
-
-
Bolignano, D.1
Palmer, S.C.2
Navaneethan, S.D.3
-
22
-
-
72749083202
-
The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective?
-
Morales E, Huerta A, Gutierrez E et al. The antiproteinuric effect of the blockage of the renin-angiotensin-aldosterone system (RAAS) in obese patients. Which treatment option is the most effective?. Nefrologia 2009; 29: 421-429
-
(2009)
Nefrologia
, vol.29
, pp. 421-429
-
-
Morales, E.1
Huerta, A.2
Gutierrez, E.3
-
23
-
-
84874521311
-
Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases
-
Morales E, Millet VG, Rojas-Rivera J et al. Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases. Nephrol Dial Transplant 2013; 28: 405-412
-
(2013)
Nephrol Dial Transplant
, vol.28
, pp. 405-412
-
-
Morales, E.1
Millet, V.G.2
Rojas-Rivera, J.3
-
24
-
-
44049101711
-
Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan
-
Vogt L, Waanders F, Boomsma F et al. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008; 19: 999-1007
-
(2008)
J Am Soc Nephrol
, vol.19
, pp. 999-1007
-
-
Vogt, L.1
Waanders, F.2
Boomsma, F.3
-
25
-
-
0031748479
-
The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide
-
Buter H, Hemmelder MH, Navis G et al. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 1998; 13: 1682-1685
-
(1998)
Nephrol Dial Transplant
, vol.13
, pp. 1682-1685
-
-
Buter, H.1
Hemmelder, M.H.2
Navis, G.3
-
26
-
-
84899980423
-
Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: A randomised clinical trial
-
Holland Nephrology Study (HONEST) Group
-
Kwakernaak AJ, Krikken JA, Binnenmars SH et al; Holland Nephrology Study (HONEST) Group. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial. Lancet Diabetes Endocrinol 2014; 2: 385-395
-
(2014)
Lancet Diabetes Endocrinol
, vol.2
, pp. 385-395
-
-
Kwakernaak, A.J.1
Krikken, J.A.2
Binnenmars, S.H.3
-
27
-
-
20544471164
-
Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents
-
Esnault VL, Ekhlas A, Delcroix C et al. Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. J Am Soc Nephrol 2005; 16: 474-481
-
(2005)
J Am Soc Nephrol
, vol.16
, pp. 474-481
-
-
Esnault, V.L.1
Ekhlas, A.2
Delcroix, C.3
-
28
-
-
77954341674
-
Diuretic uptitration with half dose combined ACEI+ARB better decreases proteinuria than combined ACEI+ARB uptitration
-
Esnault VL, Ekhlas A, Nguyen JM et al. Diuretic uptitration with half dose combined ACEI+ARB better decreases proteinuria than combined ACEI+ARB uptitration. Nephrol Dial Transplant 2010; 25: 2218-2224
-
(2010)
Nephrol Dial Transplant
, vol.25
, pp. 2218-2224
-
-
Esnault, V.L.1
Ekhlas, A.2
Nguyen, J.M.3
-
29
-
-
0037382169
-
Amiloride reduces stroke and renal injury in stroke-prone hypertensive rats
-
Sepehrdad R, Chander PN, Oruene A et al. Amiloride reduces stroke and renal injury in stroke-prone hypertensive rats. Am J Hypertens 2003; 16: 312-318
-
(2003)
Am J Hypertens
, vol.16
, pp. 312-318
-
-
Sepehrdad, R.1
Chander, P.N.2
Oruene, A.3
-
30
-
-
84862119511
-
Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria
-
Zhang B, Xie S, Shi W et al. Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria. Nephrol Dial Transplant 2012; 27: 1746-1755
-
(2012)
Nephrol Dial Transplant
, vol.27
, pp. 1746-1755
-
-
Zhang, B.1
Xie, S.2
Shi, W.3
-
31
-
-
33845238078
-
Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: Possible contribution of fat-derived factors
-
Nagase M, Yoshida S, Shibata S et al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol 2006; 17: 3438-3446
-
(2006)
J Am Soc Nephrol
, vol.17
, pp. 3438-3446
-
-
Nagase, M.1
Yoshida, S.2
Shibata, S.3
-
32
-
-
47649085301
-
Aldosterone and glomerular podocyte injury
-
Nagase M, Fujita T. Aldosterone and glomerular podocyte injury. Clin Exp Nephrol 2008; 12: 233-242
-
(2008)
Clin Exp Nephrol
, vol.12
, pp. 233-242
-
-
Nagase, M.1
Fujita, T.2
-
33
-
-
0031600240
-
Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats
-
Rocha R, Chander PN, Khanna K et al. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998; 31: 451-458
-
(1998)
Hypertension
, vol.31
, pp. 451-458
-
-
Rocha, R.1
Chander, P.N.2
Khanna, K.3
-
34
-
-
0024324630
-
Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril
-
Heeg JE, de Jong PE, van der Hem GK et al. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989; 36: 272-279
-
(1989)
Kidney Int
, vol.36
, pp. 272-279
-
-
Heeg, J.E.1
De Jong, P.E.2
Van Der Hem, G.K.3
-
35
-
-
79953053474
-
Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: A post hoc analysis of the combined RENAAL and IDNT trials
-
Holtkamp FA, de Zeeuw D, de Graeff PA et al. Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. Eur Heart J. 2011; 32: 1493-1499
-
(2011)
Eur Heart J.
, vol.32
, pp. 1493-1499
-
-
Holtkamp, F.A.1
De Zeeuw, D.2
De Graeff, P.A.3
-
36
-
-
0037309569
-
Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies
-
Morales E, Valero MA, León M et al. Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J Kidney Dis 2003; 41: 319-327
-
(2003)
Am J Kidney Dis
, vol.41
, pp. 319-327
-
-
Morales, E.1
Valero, M.A.2
León, M.3
-
37
-
-
79960407033
-
An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function
-
Holtkamp FA, de Zeeuw D, Thomas MC et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int 2011; 80: 282-287
-
(2011)
Kidney Int
, vol.80
, pp. 282-287
-
-
Holtkamp, F.A.1
De Zeeuw, D.2
Thomas, M.C.3
-
38
-
-
3442886513
-
Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study
-
Juurlink DN, Mamdani MM, Lee DS et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543-551.
-
(2004)
N Engl J Med
, vol.351
, pp. 543-551
-
-
Juurlink, D.N.1
Mamdani, M.M.2
Lee, D.S.3
|